To assess the applicability of the National Institutes of Health (NIH) consensus criteria (NCC) for chronic graft-versus-host disease (cGVHD), 211 patients who developed GVHD more than 100 days after allogeneic transplantation were reclassified using NCC. Classifications were: late acute GVHD (44 patients, 21%), overlap syndrome (64 patients, 30%) and classic cGVHD (103 patients, 49%). Classic cGVHD and overlap syndrome patients (n ¼ 167) were graded using both the revised Seattle criteria (RSC) and NIH global scoring (NGS). Twenty-three patients (14%) had mild, 81 (48%) had moderate and 63 (38%) had severe cGVHD. After a median follow-up of 46 months (range 5-71 months), the 4-year GVHD-specific survival was not significantly different among the different subtypes of NCC. Among patients with late acute GVHD, however, the pattern of acute GVHD onset (late, persistent or recurrent) was significantly different with respect to GVHD-specific survival. Among patients with overlap syndrome and classic cGVHD, multivariate analysis showed that NGS as well as RSC were useful in predicting survival and discontinuation of immunosuppressive therapy despite of more detailed grouping. Our study indicates that NCC is applicable. The clinical impact of NIH types and NGS should be verified through prospective studies.
Introduction
Chronic graft-versus-host disease (cGVHD) is a major complication occurring after allogeneic hematopoietic stem cell transplantation (HSCT). The syndrome has features resembling autoimmune disease and other immunological disorders. 1 Traditionally, the cGVHD is diagnosed when GVHD develops more than 100 days after HSCT. It is stratified into limited and extensive types based on clinical and laboratory features. 2 The Seattle group recently published a revised classification, which allowed for decision-making regarding systemic immunosuppression in patients with clinical extensive GVHD. 3 However, advances in HSCT practice in the past two decades have profoundly altered the natural history and presentation of both acute GVHD (aGVHD) and cGVHD and have brought previous definitions into question. 1 For instance, aGVHD may present beyond 100 days in patients receiving reduced-intensity conditioning, 4, 5 whereas manifestations of aGVHD and cGVHD can present simultaneouslyFfor example, in patients treated with donor-lymphocyte infusion.
The National Institutes of Heath (NIH) published consensus criteria for the diagnosis of cGVHD, which emphasized the manifestations of GVHD instead of the time of onset (day 100). 1 The NIH consensus criteria (NCC) proposed two new categories for GVHD (acute/chronic), each with two subcategories (classic acute and late acute/classic chronic and overlap syndrome). The new criteria also proposed a new scoring system describing the extent and severity of cGVHD for each organ or site at any given time, taking functional impact into account. Using this composite score in addition to the number of organs or sites involved, a new global scoring system has been proposed for assessing cGVHD severity. It is expected to replace the old grading system (limited versus extensive). The clinical impact of subtypes and the new NCC has not been determined. Thus, the feasibility of the NCC should be evaluated before being accepted and updated according to the results of validation studies.
In this study, we retrospectively reclassified cases of GVHD presenting after day 100 using the NCC and compared the new NIH classification with the revised seattle criteria (RSC). We then determined the incidence and outcomes of the various subtypes of GVHD and the impact of the newly developed scale for global assessment of the severity of cGVHD. Our purpose was to determine if the presence of various subtypes of GVHD as proposed by the NCC affects survival and to assess the feasibility of the new grading system compared to the RSC.
Materials and methods
This study examined 463 consecutive patients who underwent allogeneic HSCT for hematologic malignancies at the Catholic Hematopoietic Stem Cell Transplantation Center between January 2002 and December 2005, and who survived until day 100 after transplantation. To secure a homogeneous cohort, patients with the following criteria were excluded: those having received two allogeneic HSCT, donor-lymphocyte infusion, or additional stem cells with or without earlier standard dose chemotherapy. Ultimately, 437 patients were evaluated in this study, and 211 patients developed GVHD after day 100.
Transplant procedures
Patients received either myeloablative regimens (total body irradiation and cyclophosphamide; total body irradiation and busulfan; total body irradiation, cytarabine, and melphalan; busulfan and cyclophosphamide) or reduced-intensity regimens (fludarabine and busulfan ± antithymocyte globulin; fludarabine and melphalan; procarbazine, cyclophosphamide, and antithymocyte globulin; fludarabine, cyclophosphamide, and antithymocyte globulin). Overall, 140 patients received bone marrow stem cells, and 39 received granulocyte colonystimulating factor-mobilized peripheral blood stem cells. On the basis of our previous experience with high-dose stem cell transplantation, 6, 7 32 patients received granulocyte colonystimulating factor-primed unmanipulated bone marrow plus CD34
þ -enriched peripheral blood stem cells, due to the risk of graft failure. Human leukocyte antigen (HLA) matching was based on serologic typing for HLA-A, -B and -C antigens and molecular typing for HLA DRB1. Granulocyte colony-stimulating factor was administered to all patients at a dose of 5 mg/kg per day subcutaneously from day 7 after the transplant until neutrophil recovery. The other general transplantation procedures were performed as described in previous reports. 8, 9 Diagnosis and management of GVHD Diagnoses of aGVHD were made as previously described by consensus criteria. 10 The primary treatment for aGVHD consisted of methylprednisolone 2 mg/kg or an equivalent dose of prednisone. The treatment of steroid-refractory aGVHD was variable, as described in a previous report.
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Patients with a persistent or new diagnosis of GVHD after day 100 were classified as limited or extensive based on the RSC. 3 The treatment of cGVHD was variable, but general rules were followed: limited type was treated with topical immunosuppressant, and extensive type was treated with a calcineurin inhibitor along with systemic steroids (prednisone or methylprednisolone). Patients with cGVHD were treated until all symptoms of cGVHD were resolved or stabilized, and subsequent tapers of immunosuppressive drugs were attempted.
Reclassification of GVHD
All patients (n ¼ 211) having clinical symptoms, signs or laboratory manifestation of GVHD after day 100 were reclassified using NCC, which were applied stringently. 1 GVHD occurring after day 100 was reclassified as late aGVHD or cGVHD (classic chronic and overlap syndrome) ( Figure 1 ). We applied the NIH categories according to manifestations at the onset of GVHD, for the purpose of assessing outcomes after initial presentation. The subcategories of late aGVHD included persistent, recurrent or late-onset aGVHD features of aGVHD without diagnostic or distinctive manifestations of cGVHD occurring beyond 100 days. The diagnosis of cGVHD was made if there was at least one diagnostic clinical sign of cGVHD or at least one distinctive manifestation confirmed by pertinent biopsy or other relevant tests, along with the exclusion of other possible diagnoses. The classic cGVHD and overlap syndrome were included in the broad category of cGVHD: (1) classic cGVHD without features characteristic of aGVHD and (2) overlap syndrome in which features of aGVHD and cGVHD appear together. Patients who had classic cGVHD or overlap syndrome were scored using the NIH recommended criteria, and a global severity score of mild, moderate or severe was assigned. 1 Patients with late-onset, persistent or recurrent aGVHD were not scored, and severity assessments were not assigned.
Statistical analysis
To find factors at the onset of GVHD affecting clinical outcomes, the following clinical parameters were assessed: patient age, gender, diagnosis, disease status at transplantation, donor type, HLA match, stem cell source, donor-recipient sex match, conditioning regimen, GVHD prophylaxis, platelet count and bilirubin level at the time of GVHD diagnosis, presence of aGVHD before day 100, RSC, subtype proposed by NCC and global scoring on NCC (only patients with cGVHD, such as classic cGVHD and overlap syndrome).
Two major statistical end points of this study to identify the factors that could affect the outcome of cGVHD were GVHD-specific survival and the discontinuation of immunosuppressive therapy. GVHD-specific survival was defined as the interval from the onset of GVHD to death due to GVHD-related complications, in the absence of relapse of underlying malignancy after the onset of GVHD. Patients who had relapses of their underlying malignancies and who died of causes other than GVHD-related complications were censored at the time of the relapse and at the time of death, respectively. In addition, among patients with cGVHD, such as classic cGVHD and overlap syndrome, variables at the onset of cGVHD were evaluated to determine factors predicting the discontinuation of immunosuppressive therapy. The duration of therapy was calculated from the onset of GVHD to the day of discontinuation of immunosuppressant or last contact.
The values for categorical variables were analyzed using a w 2 or Fisher's exact test to compare differences in proportions Figure 1 Reclassification of GVHD after day 100 by NIH consensus criteria. We classified patients as having late acute GVHD if they had only acute features (no chronic features) during the course of GVHD. If patients had any chronic features, they were classified as having chronic GVHD at the onset of chronic features, and subdivided as classic chronic GVHD and overlap syndrome based on whether they had concurrent acute features. GVHD, graft-versus-host disease.
of subtypes for each classification. The curves for the GVHD-specific survival were plotted using the Kaplan-Meier method and compared using a log-rank test. Factors predicting the discontinuation of immunosuppressant were also compared using a log-rank test. For multivariate analysis, variables with a P-value o0.1, as determined by univariate analysis, were considered for entry into the model selection procedure on the basis of the Cox proportional hazards model. The final models were selected using the backward conditional method with a predetermined risk of 0.1. Statistical analyses were performed using SPSS 11.5 software (SPSS, Chicago, IL, USA) and SAS 8.2 software package (SAS Institute Inc., Cary, NC, USA).
Results
Among the 437 patients who were enrolled in the study, GVHD developed after day 100 in 211 patients (the 4-year cumulative incidence, 36.6%), and the median duration of follow-up was 46 months (range, 5-71 months). Those patients (the first cohort) were reclassified to see how the presence of various subtypes of GVHD after day 100, as proposed by the NCC, affects clinical outcomes. In addition, 167 patients with classic cGVHD (n ¼ 103) or overlap syndrome (n ¼ 64), which belonged to the cGVHD group by NCC (the second cohort), were analyzed to assess the feasibility of the new grading system (NIH global scoring, NGS ) compared to the RSC. Table 1 gives the detailed demographic information and disease and transplant characteristics of the two cohorts.
The first cohort (GVHD reclassification)
Of the 211 patients who developed GVHD after day 100, 84 (40%) were classified as having limited cGVHD, and 127 (60%) were classified as having extensive cGVHD by the RSC. There was significantly shorter GVHD-specific survival (77%, P ¼ 0.001) in patients with extensive cGVHD, compared to those with limited cGVHD (96%). According to the NCC, 211 patients were reclassified as having late aGVHD (44 patients, 21%), overlap syndrome (64 patients, 30%) or classic cGVHD (103 patients, 49%) ( Figure 1 ). Late aGVHD (n ¼ 44) consisted of late-onset (22 patients, 50%), persistent (14 patients, 32%) and recurrent (8 patients, 18%) subtypes. Each type by NCC consisted of a significantly different proportion of subtypes (limited or extensive) according to the RSC (Po0.001), and notably, overlap syndrome consisted of mainly extensive cGVHD, compared to other subtypes (Figure 2a ). There were no differences in GVHD-specific survival with regard to the NIH type of GVHD (P ¼ 0.518, Figure 3a) . In addition, patients with aGVHD features (late acute and overlap syndrome) showed no differences in clinical outcomes compared to those with classic cGVHD. In contrast, among patients with late aGVHD (n ¼ 44), there were significant differences in 4-year GVHD-specific survival (100 vs 86 vs 56%) according to the pattern of presentation (late-onset, persistent and recurrent subtypes, respectively; P ¼ 0.009, Figure 3b) . The results of univariate and multivariate analysis associated with survival are shown in Table 2 . On multivariate analysis, the RSC and the presence of aGVHD before day 100 significantly were associated with GVHD-specific survival.
The second cohort (patients with cGVHD by NCC) Severity of cGVHD. The 167 patients with classic cGVHD and overlap syndrome were graded as mild (23 patients, 14%), moderate (81 patients, 48%) or severe (63 patients, 38%) by NCC global scoring (Figure 2b ). Moderate cGVHD consisted of a more extensive type (62%) vs a limited type (38%) according to the RSC, while patients with mild or severe cGVHD consisted of mainly limited (87%) or extensive types (97%), respectively. On univariate analysis, the NGS (P ¼ 0.011) as well as RSC (P ¼ 0.003) were significant factors predicting GVHD-specific survival. Figure 4 shows that survival was different according to the definition of both the RSC and the NGS. Cox proportional multivariate models were separately constructed using the RSC and NIH consensus classification, due to a substantial concordance between two grading systems. Age at transplantation and type of donor were adjusted for in both models (Table 3) . Notably, NGS at the onset of cGVHD also had predictive value for survival, despite the more detailed classification. Prediction for the discontinuation of immunosuppressive therapy. In the second cohort, various factors at the time of GVHD diagnosis were evaluated to determine factors predicting the discontinuation of immunosuppressive therapy. The results of univariate and multivariate analysis are shown in Table 4 .
Due to the concordance between the revised Seattle classification and NIH consensus classification, Cox proportional multivariate models were separately constructed using both of them. The multivariate analysis revealed that the use of peripheral blood stem cells as a stem cell source and the greater severity of NGS as well as RSC were significant independent factors predicting lower likelihood for the discontinuation of immunosuppressive therapy.
Discussion
Chronic GVHD is the leading cause of non-relapse mortality affecting long-term survivors of allogeneic HSCT. 12 The risk of cGVHD is increasing because of the expansion of the donor population beyond HLA-identical siblings, the rising recipient age, the use of peripheral blood cells as the graft source and the infusion of donor lymphocytes for treatment of recurrent malignancy after HSCT. 3 However, the incidence of cGVHD is variable; the reported incidence of cGVHD after allogeneic HSCT ranges between 6 and 80%. [13] [14] [15] The marked heterogeneity in the intensity of the conditioning regimen, the donor type, GVHD prophylaxis, graft manipulation, stem cell source and use of post-transplantation donor-lymphocyte infusion are attributed to the variable incidence of cGVHD. Furthermore, the lack of standardized diagnostic criteria has contributed to both the variable incidence and failure of prevention and therapy in cGVHD. One of the most difficult features of the management of cGVHD is making a timely diagnosis. Clinical problems spontaneously resolve in patients when the severity of cGVHD is mild or when an alternative diagnosis, including infection, is made. Such patients should be spared from the toxicity of unnecessary immunosuppressive regimens. Conversely, patients with less common manifestations of cGVHD have been harmed by delays in the institution of appropriate therapy. The most common classification system in use stratifies cGVHD into limited and extensive subtypes and is based on the results of a small retrospective study from the pre-cyclosporine era, 2 which was then revised by the Seattle group in 2003. 3 With theses classifications, any manifestations of GVHD that are present (or continue) at 100 days after HSCT have been arbitrarily defined as cGVHD, even if the clinical manifestations are indistinguishable from those of acute GVHD. 2, 3 In this study, the RSC was demonstrated to be useful in predicting survival outcomes. However, this classification is disadvantageous in that they cannot indicate the altered presentation of GVHD in the wake of recent advances in HSCT practiceFfor example, simultaneous onset of aGVHD and cGVHD and aGVHD after day 100. In addition, interobserver variability has impaired the development of a common platform for the diagnosis and classification of cGVHD.
The present study evaluating the feasibility of NCC for cGVHD, which conceptually could overcome the shortcomings of old classifications, demonstrates that it can be effectively applied to diagnosis and staging of cGVHD. As to the impact of subtypes of GVHD after day 100 on clinical outcomes, in a similar analysis of 73 patients, the survival of patients with various types of GVHD as proposed by the NIH criteria was significantly different. 16 The differences were more apparent when patients with any acute features of GVHD were compared to those with classic cGVHD. Patients with features of aGVHD after day 100 (late acute GVHD and overlap syndrome) had worse outcomes compared to those with classic cGVHD, and acute features had poor prognostic significance. Another recent retrospective study only including sibling donor transplants, in which 54 patients developed GVHD after day 100, showed that patients with late aGVHD by NIH criteria had worse survival outcomes compared to those with classic cGVHD and overlap syndrome. 17 In our cGVHD cohort Figure 4 The GVHD-specific survival in the second cohort (GVHD severity). The GVHD-specific survival was significantly different according to both (a) the revised Seattle criteria and (b) the NIH global score. Notably, NIH global scoring at the onset of chronic GVHD also had predictive value, despite the more detailed classification. GVHD, graft-versus-host disease. as determined by the RSC for diagnosis of cGVHD, 44 (21%) of 211 patients were re-classified to late aGVHD including persistent, recurrent and late-onset GVHD. Our results are contradictory to the recent retrospective studies. 16, 17 There were no differences in survival between patients with late aGVHD and those with other subtypes, including classic cGVHD and overlap syndrome. Instead, among patients with late acute GVHD, the subtypes correlated with survival, which suggests that the onset pattern of late aGVHD symptoms rather than the presence of aGVHD features might be an important factor in predicting clinical outcomes.
Patients with overlap syndrome manifested a higher proportion of extensive disease (91%) compared to those with other subtypes (late acute (29%) and classic chronic (54%)), because the involvement of two or more organs was one of the criteria for extensive type under the RSC, 3 but this did not have an impact on clinical outcomes in our cohort. It is likely that the pattern of presentation and type of involved organs may affect clinical outcome in patients with overlap syndrome. Additional research is under way to more clearly evaluate the new category by NIH criteria.
The NIH consensus report has also proposed a global scoring system addressing the number of organs or sites involved and the severity in each affected organ. 1 We applied this scale only to patients with classic cGVHD and overlap syndrome, which are included in cGVHD by the new NIH criteria. On multivariate analyses, there were significant associations with GVHD-specific survival according to the NGS as well as the RSC in our study. In addition, the predictive value of NGS for the discontinuation of immunosuppressive therapy was revealed despite of more detailed grouping compared to the RSC. The clinical impact of the global scoring system has not been evaluated, and recent retrospective studies including a small number of patients have failed to demonstrate the applicability of NGS. 16, 17 In contrast, our study included a large number of patients and showed that the global scoring system for the assessment of cGVHD severity (mild, moderate or severe) was helpful and offered detailed grouping. This means that it would be reasonable to decide how to treat GVHD based on NGS at the onset of GVHD. The old grading system is of little practical utility because it basically divides patients into those who need treatment (extensive cGVHD) and those who do not (limited cGVHD). 18 In the future, more stratified therapeutic strategies will be available through further prospective studies for the treatment and prophylaxis of cGVHD using new NIH grading system that could make more detailed grouping possible.
Although our study was limited by its retrospective nature and recording bias, our data demonstrate the applicability of the new NIH criteria and the possible role of a new global scoring system in assessing the severity of cGVHD and determining treatment strategies. It will be important to verify the NCC through prospective multicenter studies. Finally, confirmed standard criteria will be a cornerstone in investigating Table 4 Analyses for factors predicting the discontinuation of immunosuppressive therapy in the second cohort (patients with chronic GVHD by NIH consensus criteria) Abbreviations: BM, bone marrow; CI, confidence interval; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; PB, peripheral blood.
pathophysiology and in improving prevention and treatment for cGVHD.
